CABOMETYX® (cabozantinib) Clinical Trials in Advanced Renal Cell Carcinoma

Two pivotal trials were conducted to provide clinical data to support the use of CABOMETYX^®(cabozantinib) in advanced renal cell carcinoma (RCC).

The CABOSUN study

In the pivotal, phase II, CABOSUN study, the efficacy and safety of cabozantinib was compared with sunitinib in the first-line treatment of RCC.^{1, 7, 8}

The METEOR study

In the pivotal, phase III, METEOR study, the efficacy and safety of cabozantinib following prior vascular endothelial growth factor (VEGF)-targeted therapy was compared with everolimus in treatment for RCC.^{1, 9–11}

View References →

© Ipsen Group 2020 Last updated on: October 2019. This site is published by Ipsen, which is solely responsible for the content. It is intended only for healthcare professionals from the EU – excluding France. Healthcare professionals from outside the EU, as well as any non-healthcare professionals, are excluded from the intended audience. CBZ-ALL-001685

Cabometyx in Europe

The CABOSUN study

The METEOR study

Welcome to Cabometyx.se website. This website is intended for Sweden Healthcare professionals only.

Please confirm below that you are a registered healthcare professional.